Colorado Therapeutics

CO - Louisville

Biotechnology2 H-1B visas (FY2023)

Website LinkedIn Careers Page

Focus: Crosslinked Soft Tissue Repair Material

Colorado Therapeutics is a life sciences company focused on Crosslinked Soft Tissue Repair Material.

Oncology

Funding Stage

PRIVATE

Open Jobs

Products & Portfolio (2)

CYPROHEPTADINE HYDROCHLORIDE

cyproheptadine hydrochloride

Post-LOE

ORAL · TABLET

CLINICAL PHARMACOLOGY Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites. Pharmacokinetics and Metabolism After a single 4 mg oral dose of C-labelled cyproheptadine hydrochloride in normal subjects, given as tablets, 2% to 20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12 mg to 20 mg daily doses. The principle metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency.

2003

GRISEOFULVIN, ULTRAMICROSIZE

ultramicrosize griseofulvin tablets

Post-LOE

ORAL · TABLET

CLINICAL PHARMACOLOGY Microbiology Griseofulvin is fungistatic with in vitro activity against various species of Microsporum, Epidermophyton and Trichophyton . It has no effect on bacteria or other genera of fungi. Pharmacokinetics Following oral administration, griseofulvin is deposited in the keratin precursor cells and has a greater affinity for diseased tissue. The drug is tightly bound to the new keratin which becomes highly resistant to fungal invasions. The efficiency of gastrointestinal absorption of ultramicrocrystalline griseofulvin is approximately one and one-half times that of the conventional microsize griseofulvin. This factor permits the oral intake of two-thirds as much ultramicrocrystalline griseofulvin as the microsize form. However, there is currently no evidence that this lower dose confers any significant clinical differences with regard to safety and/or efficacy. In a bioequivalence study conducted in healthy volunteers (N=24) in the fasted state, 250 mg ultramicrocrystalline griseofulvin tablets were compared with 250 mg ultramicrocrystalline griseofulvin tablets that were physically altered (crushed) and administered with applesauce. The 250 mg ultramicrocrystalline griseofulvin tablets were found to be bioequivalent to the physically altered (crushed) 250 mg ultramicrocrystalline griseofulvin tablets (see Table 1). Table 1: Mean (± SD) of the Pharmacokinetic Parameters for Griseofulvin administered in applesauce as a Single-Dose of Ultramicrosize Griseofulvin Tablets, 250 mg Uncrushed and Crushed to fasted Healthy Volunteers (N=24) 250 mg Ultramicrocrystalline Griseofulvin Tablets-Unaltered 250 mg Ultramicrocrystalline Griseofulvin Tablets-Physically Altered (Crushed and in Applesauce) C max (ng/mL) 600.61 (± 167.6) 672.61 (± 146.2) T max (hr) 4.04 (± 2.2) 3.08 (± 1.02) AUC (ng∙hr/mL) 8,618.89 (± 1,907.2) 9,023.71 (± 1,911.5)

the following ringworm infections

2014

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 approved products, 30 clinical trials

Top TAs: Metabolic Diseases, Oncology, Neurology

H-1B (2023): 2 approvals

Portfolio Health

Post-LOE2 (100%)

2 total products

Therapeutic Area Focus

4 pipeline

1 marketed2 pipeline

2 pipeline

1 pipeline

1 pipeline

1 pipeline

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub